United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

10 glass vials -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - colistimethate sodium - powder for solution for injection - 1000000unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - colistimethate sodium - ear drops - 10mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

zambon s.p.a. - colistin mesilate sodium - powder for nebuliser solution - 1 million international unit - polymixins

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sudair pharma company, saudi arabia - colistimethate sodium - powder for solution for injection/infusion - 1,000,000 iu

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - colistimethate sodium 384.6 mg/ml - powder for injection - 150 mg/2ml - active: colistimethate sodium 384.6 mg/ml - the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli; particularly when the infection is caused by sensitive strains of pseudomonas aeruginosa, and the following gram-negative organisms; aerobacter aerogenes, escherichia coli, klebsiella pneumoniae. pending results of appropriate bacteriologic cultures and sensitivity tests, colistimethate sodium may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms.

European Union - English - myHealthbox

forest laboratories uk ltd - colistimethate sodium - inhalation powder, hard capsule - each capsule contains 1662500iu (approximately equal to 125mg) of colistimethate sodium - cystic fibrosis - antibacterials for systemic use - colobreathe is indicated for the management of chronic pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis (cf) aged 6 years and older

Canada - English - Health Canada

sterimax inc - colistin (colistimethate sodium) - powder for solution - 150mg - colistin (colistimethate sodium) 150mg - polymyxins

Canada - English - Health Canada

fresenius kabi canada ltd - colistin (colistimethate sodium) - powder for solution - 150mg - colistin (colistimethate sodium) 150mg - polymyxins

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistin 150 mg in 2 ml - coly-mycin m parenteral is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa . this antibiotic is not indicated for infections due to proteus or neisseria . coly-mycin m parenteral has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa. coly-mycin m parenteral may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of coly-mycin m and other antibacterial drugs, coly-mycin m should be used only to treat or prevent infections that are proven or strongly suspected to be caused by s